Turkiye Klinikleri Journal of Dermatology

.: REVIEW
Primer Kutanöz Lenfomalarda Tanı ve Evreleme
Diagnosis and Staging in Primary Cutaneous Lymphomas
Esra PANCAR YÜKSELa
aOndokuz Mayıs Üniversitesi Tıp Fakültesi, Deri ve Zührevi Hastalıkları ABD, Samsun, TÜRKİYE
Turkiye Klinikleri J Dermatol. 2020;30(2):56-62
doi: 10.5336/dermato.2019-72771
Article Language: TR
Full Text
ÖZET
 Primer kutanöz lenfomalar, kutanöz T hücreli ve B hücreli lenfomaların heterojen bir grubudur. Tanı aldıklarında çoğunlukla deriye lokalizedirler. Yaklaşık %80'ini kutanöz T hücreli lenfomalar, %20'sini kutanöz B hücreli lenfomalar oluşturmaktadır. Tanı için klinik, histopatoloji, immünfenotiplendirme ve gen rearranjman analizleri birlikte değerlendirilmelidir. En sık görülen kutanöz T hücreli lenfoma mikozis fungoidestir. Klinik olarak yama, plak ve tümöral lezyonlar görülür. Histopatolojik incelemede atipik lenfositler, epidermotropizm, Pautrier mikroapseleri tespit edilir. Fakat histopatolojik bulgular ve immünfenotiplendirme karakteristik olmadığında, erken evre mikozis fungoideste tanı zorlukları yaşanmaktadır. Eritrodermi ile karakterize Sezary sendromunda, Sezary hücreleri deride, lenf nodunda ve periferik kanda görülür. Primer kutanöz CD30+ lenfoproliferatif hastalıklar ise kutanöz T hücreli lenfomaların 2. büyük grubunu oluşturur. Bunlar dışında nadir görülen diğer primer kutanöz T hücreli lenfomalar için klinik, histopatolojik, immünfenotiplendirme özellikleri ile ayırıcı tanıya gidilir. Primer kutanöz marjinal zon lenfoma, primer kutanöz folikül merkez hücreli lenfoma, primer kutanöz diffüz büyük B hücreli lenfoma, bacak tipi ise başlıca 3 primer kutanöz B hücreli lenfomadır. Primer kutanöz lenfoma hastalarında evreleme yapılması hastaların takibi, prognozu ve tedavisi için önemlidir. Mikozis fungoides ve Sezary sendromu için TNMB sınıflandırması kullanılır. Derinin değerlendirilmesi için lezyonların klinik özellikleri ve kapladıkları yüzey alan önemlidir. Anormal lenf nodlarının incelenmesi için eksizyonel biyopsi önerilir. Lenf nodlarında, prognoz nodal yapının silinmesi ile ilişkilidir. Diğer primer kutanöz lenfomaları evrelendirmek için TNM sınıflandırması kullanılır ve santral lenf nodları değerlendirilir.

Anahtar Kelimeler: Kutanöz B hücreli lenfoma; kutanöz T hücreli lenfoma; primer kutanöz lenfoma
ABSTRACT
 Primary cutaneous lymphomas are a heterogeneous group of cutaneous T and B cell lymphomas. They present in the skin with no evidence of extracutaneous disease at the time of diagnosis. Cutaneous T cell lymphomas represent approximately 80% and cutaneous B cell lymphomas represent approximately 20% of all primary cutaneous lymphomas. Clinical properties, histopathology, immunophenotyping and gene rearrangement analyzes are evaluated for the diagnosis. Mycosis fungoides represents the most common type of cutaneous T cell lymphomas and presents in the skin as patches, plaques and tumors. Histopathological examination reveals atypical lymphocytes, epidermotropism and Pautrier microabscesses. However, when histopathological findings and immunophenotyping are not characteristic, diagnosis of early mycosis fungoides could be difficult. Sezary syndrome is characterized by erythroderma and Sezary cells are present in the skin, lymph nodes and peripheral blood. Primary cutaneous CD30+ lymphoproliferative disorders represent the second most common group of cutaneous T cell lymphomas. For other rare primary cutaneous T cell lymphomas, differential diagnosis is made with clinical, histopathological and immunophenotyping features. Primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type are 3 types of primary cutaneous B-cell lymphomas. Staging is important for the follow up, prognosis and treatment of the patients with primary cutaneous lymphomas. Staging of mycosis fungoides and Sezary syndrome is based on TNMB classification. Clinical features and surface area of the lesions are important for the evaluation of the skin. Excisional biopsy is recommended for examination of abnormal lymph nodes. Prognosis regarding lymph nodes is related to effaced nodal architecture. TNM classification is used for staging other primary cutaneous lymphomas and central lymph nodes are also evaluated.

Keywords: Cutaneous B-cell lymphoma; cutaneous T-cell lymphoma; primary cutaneous lymphoma
REFERENCES:
  1. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-14. [Crossref]  [PubMed]  [PMC] 
  2. Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British association of dermatologists and U.K. cutaneous lymphoma group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496-526. [Crossref]  [PubMed] 
  3. Cerroni L. Past, present and future of cutaneous lymphomas. Semin Diagn Pathol. 2017;34(1):3-14. [Crossref]  [PubMed] 
  4. Willemze R. Cutaneous T-Cell Lymphoma. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. China: Elsevier; 2018. p.2127-47.
  5. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16. [Crossref]  [PubMed] 
  6. Larocca C, Kupper T. Mycosis fungoides and sézary syndrome: an update. Hematol Oncol Clin North Am. 2019;33(1):103-20. [Crossref]  [PubMed]  [PMC] 
  7. Junkins-Hopkins JM, Busam KJ, Myskowski PL, Pulitzer MP. Hematopoietic neoplasms. In: Busam K, Goldblum JR, eds. Dermatopathology. 2nd ed. Philadelphia: Saunders Elsevier; 2016.p.595-653.
  8. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85. [Crossref]  [PubMed] 
  9. Burg G, Kempf W, Cozzio A, Feit J, Willemze R, S Jaffe E, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005;32(10):647-74. [Crossref]  [PubMed] 
  10. Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(10):1085-102. [Crossref]  [PubMed] 
  11. Ormsby A, Bergfeld WF, Tubbs RR, Hsi ED. Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice. J Am Acad Dermatol. 2001;45(3):405-13. [Crossref]  [PubMed] 
  12. Michie SA, Abel EA, Hoppe RT, Warnke RA, Wood GS. Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. Am J Pathol. 1990;137(6):1447-51. [PubMed] 
  13. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R,et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol. 1994;103(1):34-41. [Crossref]  [PubMed] 
  14. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med. 1994;179(2):609-18. [Crossref]  [PubMed]  [PMC] 
  15. Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol. 2007;143(7):921-32. [Crossref]  [PubMed] 
  16. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-63. [Crossref]  [PubMed] 
  17. Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350-7. [Crossref]  [PubMed] 
  18. Dulmage BO, Geskin LJ. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol. 2013;169(6):1188-97. [Crossref]  [PubMed]  [PMC] 
  19. Yuki A, Shinkuma S, Hayashi R, Fujikawa H, Kato T, Homma E, et al. CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. J Am Acad Dermatol. 2018;79(6):1039-46. [Crossref]  [PubMed] 
  20. Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158. [Crossref]  [PubMed]  [PMC] 
  21. Kohler S, Kim YH, Smoller BR. Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sézary syndrome: a critical reappraisal. J Cutan Pathol. 1997;24(5):292-7. [Crossref]  [PubMed] 
  22. Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35(3 Pt 1):404-10. [Crossref]  [PubMed] 
  23. Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, et al. Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015;173(1):93-105. [Crossref]  [PubMed] 
  24. Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, et al. Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol. 2016;136(7):1364-72. [Crossref]  [PubMed] 
  25. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22. [PubMed] 
  26. Brown RA, Fernandez-Pol S, Kim J. Primary cutaneous anaplastic large cell lymphoma.J Cutan Pathol. 2017;44(6):570-7. [Crossref]  [PubMed] 
  27. Beljaards RC, Meijer CJ, Scheffer E, Toonstra J, van Vloten WA, van der Putte SC, et al. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol. 1989;135(6):1169-78. [PubMed] 
  28. Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, et al. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin. Chin Clin Oncol. 2019;8(1):3. [Crossref]  [PubMed] 
  29. Nicolae-Cristea AR, Benner MF, Zoutman WH, van Eijk R, Jansen PM, Tensen CP, et al. Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease. Br J Dermatol. 2015;172(3):784-8. [Crossref]  [PubMed] 
  30. Fauconneau A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, et al. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Br J Dermatol. 2015;172(6):1547-54. [Crossref]  [PubMed] 
  31. Sauder MB, O'Malley JT, LeBoeuf NR. CD30+ Lymphoproliferative Disorders of the Skin. Hematol Oncol Clin North Am. 2017;31(2):317-34. [Crossref]  [PubMed]  [PMC] 
  32. Chen C, Gu YD, Geskin LJ. A review of primary cutaneous CD30+ lymphoproliferative disorders. Hematol Oncol Clin North Am. 2019;33(1):121-34. [Crossref]  [PubMed] 
  33. Damasco F, Akilov OE. Rare Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am. 2019;33(1):135-48. [Crossref]  [PubMed] 
  34. Goyal A, LeBlanc RE, Carter JB. Cutaneous B-Cell Lymphoma. Hematol Oncol Clin North Am. 2019;33(1):149-61. [Crossref]  [PubMed] 
  35. Cerroni L. B-Cell Lymphomas of the Skin. In: Bolognia JL, Schaffer JV, Cerroni L,eds. Dermatology. 4th ed. China: Elsevier; 2018. p.2113-26.
  36. Suárez AL, Pulitzer M, Horwitz S, Moskowitz A, Querfeld C, Myskowski PL. Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification. J Am Acad Dermatol. 2013;69(3):329.e1-13. [Crossref]  [PubMed] 
  37. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19(16):3602-10. [Crossref]  [PubMed] 
  38. Larocca CA, LeBoeuf NR. Overview of Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am. 2019;33(4):669-86. [Crossref]  [PubMed] 
  39. Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin. 2015;33(4):643-54. [Crossref]  [PubMed] 
  40. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-84. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com